News Conference News AHA 2018 Rivaroxaban Lowers Thromboembolic Risk in HF Patients: COMMANDER HF Todd Neale November 11, 2018
News Daily News New-Onset A-fib Following Noncardiac Surgery: Beware the Thromboembolic Risk Yael L. Maxwell October 16, 2018
News Daily News Patients With A-fib and Cancer May Benefit From Visiting With a Cardiologist Early On Todd Neale October 10, 2018
News Daily News DOACs Safe, Effective in A-fib Patients With Preexisting LAA Thrombus Caitlin E. Cox October 04, 2018
News Daily News Stay Away From Warfarin-Based Triple Therapy in Patients With A-fib and CAD, Study Affirms Todd Neale October 03, 2018
News Conference News ESC 2018 Atrial Fibrillation, Oral Anticoagulation Linked With Mortality After TAVR: FRANCE-TAVI Michael O'Riordan August 25, 2018
News Daily News Edoxaban Looks Good for Asians With A-fib in Real-world Analysis Todd Neale August 14, 2018
News Daily News New Consensus Statement: NOAC and Clopidogrel for Most A-fib Patients Treated With PCI Michael O'Riordan July 31, 2018
News Daily News Asian Patients With A-fib Don’t Gain Anything From Low-Dose Rivaroxaban Todd Neale July 24, 2018
News Daily News NOACs Particularly Beneficial for Women With A-fib, Study Suggests Todd Neale July 11, 2018
News Daily News Oral Anticoagulation Boosts Poststroke Outcomes in Patients With A-fib Todd Neale May 18, 2018
News Conference News SCAI 2018 Doctors, Risk Tools Often at Odds When Assessing Risks in Patients With A-fib Undergoing PCI Todd Neale April 27, 2018
News Daily News Less Bleeding, Similar Outcomes With Dual vs Triple Therapy After PCI in Patients With A-fib Todd Neale April 24, 2018
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for March 2018 Shelley Wood April 02, 2018
News Conference News ACC 2018 Apixaban Has Edge Over Other NOACs in Large, Real-World Analysis Todd Neale March 12, 2018
News Conference News ISC 2018 Experts Debate: Is It ‘Nuts’ to Restart Anticoagulation After Lobar ICH? Todd Neale January 30, 2018
News Industry News New Real-World Analysis Finds Lower Risk of Major Bleeding and Similar Risk of Stroke with Standard Dose of Pradaxa® Compared to Rivaroxaban in NVAF Patients Newly Initiating Treatment January 29, 2018
News Conference News ISC 2018 More Evidence Rivaroxaban May Carry Higher Bleeding Risk Than Other NOACs Todd Neale January 27, 2018